Upstream Bio, Inc. (UPB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$5.96-3.72%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Stabilize or improve revenue from current forecast: FY2027 revenue est -38.5% YoY vs -10% target.
Upstream Bio has $341.5M cash to fund operations through 2027. It is developing treatments for severe respiratory diseases. Some recent earnings beats show potential progress. The company aims to stabilize its finances and advance clinical trials.
The company is loss-making with negative earnings expected. Revenue is forecast to shrink about 38% next year. Recent earnings misses and litigation risks weigh on confidence. Cash may not last if progress stalls or costs rise.
The market expects about 38% revenue decline next year. Our fair value is $2.65 per share. The stock price reflects high risk and optionality in clinical outcomes.
Breaks if: cash falls below $300M before end of 2027
Ensure sufficient cash reserves to fund planned operations through 2027.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity in the healthcare sector. The current thesis state reflects uncertainty due to recent litigation and mixed financial performance.
The market appears to price UPB at a premium compared to its peers, indicating high expectations despite its loss-making status. The valuation suggests that investors may be anticipating significant future optionality.
Management has stable priorities, including advancing clinical trials, but faces risks from declining cash reserves. Recent financial performance has been neutral, with a low probability of missing expectations, though the industry is known for higher miss rates.
Key factors include the outcomes of upcoming clinical trials and the performance of sector bellwethers. Additionally, guidance cuts or worsening economic conditions could negatively impact UPB's trajectory.
The most important moves since the prior daily snapshot.
risk label changed from 'elevated' to 'high'.
Yes, our read has weakened. The latest earnings report missed expectations significantly. This miss raises concerns about future performance. The risk label changed from 'elevated' to 'high'.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: EPS loss worsens beyond -$3.0 per share in FY 2027
Breaks if: revenue decline exceeds -10% YoY in FY 2027
In the next 1 to 3 years, UPB's performance will depend heavily on its clinical advancements and broader market conditions. Not investment advice.